Introduction {#sec1}
============

Drug eluting stents (DES) coated with anti-proliferative agents have been proven to reduce the incidence of restenosis and target lesion revascularization (TLR) by inhibition of neointimal hyperplasia.[@bib1], [@bib2] However, DES are also associated with a higher rate of late stent thrombosis (LST) as compared with bare metal stents (BMS).[@bib3], [@bib4]

A permanent polymer coating is used to bind the anti-proliferative drugs to the stent platform and control the drug release. The polymer stays *in situ* after the drug is released, which can cause chronic inflammation and can delay the endothelial healing.[@bib5], [@bib6] Therefore, efforts have been made to develop stents with biodegradable polymers or with polymer-free surfaces. There have been several studies of whether polymer-free stents can produce a better clinical outcome compared with permanent polymer stents but there are conflicting results about the clinical outcomes.

This meta-analysis aims to summarize the data from randomized controlled trials (RCT) comparing permanent polymer DES (PP-DES) with polymer-free DES (PF-DES).

Methods {#sec2}
=======

Search strategy {#sec2.1}
---------------

The meta-analysis was performed according to the Cochrane handbook for systematic reviews of interventions 5.1.0.[@bib7] A systematic review was performed in MEDLINE, EMBASE, Cochrane Library, Scopus, Highwire Press and Google Scholar databases for publications until December, 2015. The search was conducted without language restriction by two independent investigators using the keywords "stent", "drug eluting", "polymer-free", "nonpolymer", "polymer" and "randomized". Endnote X6 was used to build a library of references and to erase duplicated results. Meeting abstracts that provided sufficient data were also included. Studies with overlapping data were excluded.

Selection criteria {#sec2.2}
------------------

The citations were screened at the title and abstract level then retrieved as full reports. Inclusion criteria included the following: 1) RCTs comparing PF-DES with PP-DES; 2) studies reporting clinical outcomes as all-cause death and/or cardiac death and/or myocardial infarction (MI) and/or TLR and/or LST consistent with Academy Research Consortium (ARC) definition[@bib8] and/or in-stent late lumen loss (LLL) and 3) a follow-up period longer than six months with or without quantitative coronary angiography reexamination. Exclusion criteria were: 1) duplicated reporting (in which studies with the longest follow-up time were selected); 2) using BMS or biodegradable polymer DES (BP-DES) or bioabsorbable scaffold stents or other peculiar stents. Data were abstracted on pre-specified forms by two unblinded reviewers and divergences of opinion were resolved by consensus.

Quality assessment {#sec2.3}
------------------

The quality assessment was performed according to the Cochrane handbook for systematic reviews of interventions 5.1.0.[@bib7] The quality of the studies included was appraised by two unblinded investigators. The risk of selection, performance, detection, attrition, reporting and other bias was qualified as a low risk of bias, an unclear risk of bias or a high risk of bias as recommended. The initial protocols registered in clinicaltrial.gov (<https://clinicaltrials.gov/>) were screened when qualifying a reporting bias.

Date extraction {#sec2.4}
---------------

Two blinded reviewers independently performed data extraction. Disagreements between the reviewers were resolved through discussion or by the third reviewer. The extracted data included: (1) first author\'s last name, the publication year; (2) characteristics of the study population, (3) stent types, duration of follow-up, (4) study design, and (5) study endpoints.

Endpoints and definitions {#sec2.5}
-------------------------

The composite endpoint of major adverse cardiovascular events (MACEs) was defined as the composite of all-cause death, MI, or ischemia-driven TLR. Definite or probable stent thrombosis was adjudicated using the Academic Research Consortium definite or probable criteria.[@bib8]

Data analysis {#sec2.6}
-------------

Review manager 5.2.6 was used for all analyses. Odds ratios (ORs) were computed from individual studies and pooled according to a fixed effect or random effect model in case of statistical heterogeneity. Outcomes appraised were all-cause death, MI, TLR, MACEs, LST, and in-stent LLL. We used the Mantel-Haenszel method for combining ORs of binary outcomes. The mean difference of followed-up LLL compared with baseline was used for the in-stent LLL outcomes, and the overall weighted mean difference (WMD) was built with the inverse variance method, as recommended.[@bib7]

We assessed the heterogeneity between eligible studies by the Cochrane Q test. We considered *P* values less than 0.10 as an indicator of significant heterogeneity because of the low statistical power. We also used the inconsistency index *I*^2^ to quantify heterogeneity. Funnel plots were constructed to assess publication bias.

Results {#sec3}
=======

Literature search and eligible studies {#sec3.1}
--------------------------------------

The review process is presented in [Fig. 1](#fig1){ref-type="fig"}. The literature search resulted in 140 relevant outcomes after duplicates removed. We excluded 100 reviews and irrelevant studies, and 11 studies were removed after closer inspection. The specific reasons for their exclusion were: 1) non-randomized studies or registries studies, 2) used BMS or BP-DES or other peculiar stent technologies. We excluded duplicated reports of the same studies. Finally, we considered 11 appropriate studies, one[@bib9] of which did not provide necessary data and it was excluded from this meta-analysis.Fig. 1Flow diagram of the review process.

The 10 studies[@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19] enrolling 6575 patients were included in the meta-analysis. Study follow-up duration ranged from 1 to 5 years. In ISAR-TEST-3,[@bib11] Byrne et al compared the clinical outcomes of three different polymer coating strategies (PP-DES, BP-DES and PF-DES), and we only extracted data about PP-DES and PF-DES. In the ISAR-TEST-2,[@bib10] Byrne et al compared PF-DES with two types of PP-DES, so we combined the data of the two types of PP-DES. The risk of bias assessment is presented in [Fig. 2](#fig2){ref-type="fig"}. There was no publication bias according to the funnel plot of each endpoint ([Fig. 3](#fig3){ref-type="fig"}). The main characteristics are presented in [Table 1](#tbl1){ref-type="table"} and [Table 2](#tbl2){ref-type="table"}.Fig. 2Risk of bias judgment.Fig. 3Funnel plot of comparison Polymer-free drug eluting stents (PF-DES) vs. Permanent polymer drug eluting stents (PP-DES): outcome: in-stent late stent thrombosis. Funnel plot displays no publication bias about the end-point of late stent thrombosis (LST), as demonstrated by the absence of graphical asymmetrical distribution.Table 1Characteristics of included studies.AuthorJournalAcronymPatientsTotal patientsPF-DESPF-DES drugPF-DES patientsPP-DESPP-DES drugPP-DES patientsFollow up time (year)ByrneHeart 2009ISAR-TEST-3CAD4032% rapamycinSirolimus201CypherSirolimus2022ByrneJACC 2010ISAR-TEST-2CAD1007Dual-DESSirolimus, probucol333Cypher,EndeavorSirolimus, zotarolimus6742CarrieJACC 2011--CAD296Cre8Amphilimus148Taxus LibertePaclitaxel1481DangChin Med J (Engl) 2012--STEMI105YinyiPaclitaxel50PartnerSirolimus551MassbergCirculation 2011ISAR-TEST-5CAD450Dual-DESSirolimus, probucol225ResoluteZotarolimus2251KingCatheter Cardiovasc Interv. 2013ISAR-TESTCAD3002YukonSirolimus2002TaxusPaclitaxel10005ShiratoriCatheter Cardiovasc Interv. 2014--CAD164AxxionPaclitaxel80TAXUS ExpressPaclitaxel842StiermaierCatheter Cardiovasc Interv. 2013LIPSIA YukonCAD&DM232Yukon ChoiceSirolimus118Taxus LibertePaclitaxel1145ZhangInt J Cardiol 2013--CAD648YinyiPaclitaxel327PartnerSirolimus3212ZhangChin Med J (Engl) 2014--CAD268NanoSirolimus132PartnerSirolimus1362[^1]Table 2Features of clinical trials included after full-text inspection.StudyAge (years)Male (%)Smoking (%)HBP (%)Dyslipidemia (%)Diabetes (%)ACS (%)Prior MIPrior PCIPrior CABGType B2/C lesions (%)Lesion lengthByrne 200966.0 ± 10.279.916.465.867.527.030.533.3NA10.4NA14.45 ± 6.14Byrne 201066.9 ± 11.166.718.466.765.727.441.827.0NA8.8372.514.46 ± 8.17Carrie 201164.6 ± 10.372.124.564.461.926.9NA9.015.2NA31.315.28 ± 7.03Dang 201266.2 ± 13.169.564.843.821.925.71005.71.9NA56.7NAMassberg 201167.8 ± 11.176.417.466.763.529.041.029.5NA9.574.116.57 ± 9.74King 201366.7 ± 10.376.918.266.074.429.142.931.8NA11.176.412.75 ± 6.47Shiratori 201466.5 ± 9.372.618.973.261.632.342.731.128.96.173.815.91 ± 8.81Stiermaier 201367.1 ± 9.368.625.097.5NA100NA22.030.17.636.416.74 ± 4.63Zhang 201365.6 ± 10.867.040.064.8NA26.585.5NANANA87.7NAZhang 201457.4 ± 10.476.851.653.531.116.8NA30.214.8NANA23.6 ± 13.5[^2]

Outcome analysis {#sec3.2}
----------------

### All-cause death {#sec3.2.1}

A fixed effect model was used to build up the quantitative analysis for all-cause death given that no heterogeneity was found. The 10 studies that enrolled 6539 patients were included in the analysis. Compared with PP-DES, PF-DES significantly decreased the all-cause death rate (*OR* = 0.77, 95% *CI*: 0.61 to 0.98, *P* = 0.03) ([Fig. 4](#fig4){ref-type="fig"}).Fig. 4Individual and summary odds ratios for all-causes death in patients treated by PF-DES and PP-DES implantation. PF-DES: polymer-free drug eluting stents, PP-DES: permanent polymer drug eluting stents, M--H: Mantel-Haenszel method.

### Myocardial infarction {#sec3.2.2}

A fixed effect model was used for the quantitative analysis as we found no heterogeneity. Compared with PP-DES, no significant benefit was found in the PF-DES group (*OR* = 1.12, 95% *CI*: 0.19 to 23.18, *P* = 0.39) ([Fig. 5](#fig5){ref-type="fig"}).Fig. 5Individual and summary odds ratios for myocardial infraction in patients treated by PF-DES and PP-DES implantation. PF-DES: polymer-free drug eluting stents, PP-DES: permanent polymer drug eluting stents, M--H: Mantel-Haenszel method.

### Target lesion revascularization {#sec3.2.3}

The result of TLR was available in 10 studies. We used a fixed effect model to perform the quantitative analysis as no heterogeneity was found. The PF-DES group showed no significant benefit compared with the PP-DES group (*OR* = 1.19, 95% *CI*: 0.42 to 3.38, *P* = 0.83) ([Fig. 6](#fig6){ref-type="fig"}).Fig. 6Individual and summary odds ratios for target lesion revascularization in patients treated by PF-DES and PP-DES implantation. PF-DES: polymer-free drug eluting stents, PP-DES: permanent polymer drug eluting stents, M--H: Mantel-Haenszel method.

### MACEs {#sec3.2.4}

Three of the studies met the definition of MACEs in our analysis. In other studies, we calculated the MACEs according to the corresponding results. A random effect model was used to perform the meta-analysis. The two kinds of stents showed similar results in MACEs (*OR* = 0.99, 95% *CI*: 0.79 to 1.24, *P* = 0.91) ([Fig. 7](#fig7){ref-type="fig"}).Fig. 7Individual and summary odds ratios for major adverse cardiovascular events in patients treated by PF-DES and PP-DES implantation. PF-DES: polymer-free drug eluting stents, PP-DES: permanent polymer drug eluting stents, M--H: Mantel-Haenszel method.

### Late stent thrombosis {#sec3.2.5}

We extracted definite or probable LST for further analysis. A fixed effect model was used to build up the quantitative analysis as no heterogeneity was found. The PF-DES and the PP-DES showed similar rates of LST (*OR* = 0.92, 95% *CI*: 0.05 to 5.71, *P* = 0.74) ([Fig. 8](#fig8){ref-type="fig"}).Fig. 8Individual and summary odds ratios for definite or probable late stent thrombosis in patients treated by PF-DES and PP-DES implantation. PF-DES: polymer-free drug eluting stents, PP-DES: permanent polymer drug eluting stents, M--H: Mantel-Haenszel method.

### Late lumen loss {#sec3.2.6}

A random effect model was used to perform the meta-analysis given the degree of heterogeneity found. Two of the studies[@bib10], [@bib11] performed angiography twice during follow-up (once in 6--8 month, once in 2 years), while in three studies[@bib12], [@bib13], [@bib14] it was performed once in 6--9 months. We built a meta-analysis for both short term LLL (6--9 months) and long term LLL (2 years). In the early phases, PF-DES showed no benefit in reducing LLL compared with PP-DES (WMD 0.03 mm 95% *CI*: −0.07 to 0.13 mm, *P* = 0.57). However, after reviewing the 2 years outcome, the PF-DES showed a significantly lower in-stent LLL (*OR* = 0.77, 95% *CI*: 0.61 to 0.98, *P* = 0.03) ([Fig. 9](#fig9){ref-type="fig"}).Fig. 9Individual and summary odds ratios for in-stent lumen loss in patients treated by PF-DES and PP-DES implantation at short (6--9 months) or long (2 years) term. PF-DES: polymer-free drug eluting stents, PP-DES: permanent polymer drug eluting stents, IV: inverse variance method.

Discussion {#sec4}
==========

The main finding of this meta-analysis is that compared with PP-DES, PF-DES showed superiority in reducing long-term LLL and all-cause mortality, while showed no significant benefit on short-term LLL, MI, TLR and LST.

It has been demonstrated that vascular wall inflammation may be induced after PP-DES implanted in pigs[@bib20], [@bib21] and humans.[@bib22], [@bib23] This inflammation is considered to cause delayed intimal healing, late malapposition and LST,[@bib24] and it may have an important etiological role in adverse events late after stent implantation. Permanent polymer can also aggravate neointimal atherosclerosis compared with BMS which could induce more adverse events.[@bib25] Considering that, intimal inflammation and LST have become a bottleneck problem restricting the development of DES. As a consequence, both BP-DES and PF-DES have been the focus of and have been developed. BP-DES showed superiority in reducing TLR and LLL but without clear benefits for mortality, MI, and LST.[@bib26] Nevertheless, studies also reported late inflammation after BP-DES implantation.[@bib22], [@bib27]

Several studies have evaluated the safety and efficiency of PF-DES involving different types of stent coating different agents including Paclitaxel,[@bib16], [@bib28] sirolimus,[@bib10], [@bib11], [@bib13], [@bib14], [@bib15] biolimus[@bib29] and amphilimus.[@bib12] This meta-analysis included 10 studies comparing polymer-free paclitaxel, sirolimus and amphilimus eluting stents with PP-DES with 1--5 years follow-up duration. PF-DES coated with biolimus were not included due to absence of the necessary data.

Given that two (2)[@bib10], [@bib11] of the studies didn\'t provide data on cardiac death, we analyzed rates of all-cause death to evaluate the efficiency of PF-DES in reducing mortality. It showed that PF-DES could significantly reduce mortality without any detectable heterogeneity so that this may be convincing evidence in the evaluation of PF-DES.

Another noteworthy finding of this meta-analysis was that compared with PP-DES, PF-DES had a similar LLL 6--9 months after stent implantation, while it showed significant benefit in long-term follow-up. Because of a higher speed of drug release (∼75% in the first 10 days), PF-DES may have relatively higher initial lumen loss in 6--9 months compared with PP-DES. However, it may consequently prompt earlier and more complete vessel healing than PP-DES. It has been demonstrated that additional lumen loss was found in PP-DES implanted vessels even beyond 6--9 months.[@bib30], [@bib31] It might also be proposed that existence of a polymer induced more inflammation and higher lumen loss.[@bib32]

No benefit in reducing TLR, MI and LST of PF-DES was found in this meta-analysis. Among the 10 studies, two (2) of them had a 5-year follow-up time while the other eight (8) studies followed up for 1 or 2 years. A short duration of follow-up might make it difficult to detect endpoints with low incidences even though we had a large sample size. Further studies with larger sample size and longer follow-up duration need to be performed in the future.

Limitations {#sec5}
===========

We did not have access to the data of the Biofreedom FIM study,[@bib9] even though we made a great effort, and it might have been important for this analysis. The coating agents and follow-up duration ranged among different studies, which lead to heterogeneity in the analysis. Finally, we could not get access to individual patient data which prevented us from making subgroup analysis; such as acute coronary syndrome, diabetes, and other meaningful clinical conditions.

Conclusion {#sec6}
==========

In this meta-analysis, PF-DES showed benefit on reducing long-term LLL and all-cause mortality compared with PP-DES, but no superiority was found in short-term LLL, MI, TLR and LST. These findings provide a sound basis to wide application of PF-DES in the future.
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[^1]: PF-DES: polymer-free drug eluting stents, PP-DES: permanent polymer drug eluting stents, CAD: coronary artery disease, STEMI: ST elevated myocardial infarction, DM: diabetes mellitus.

[^2]: HBP: high blood pressure, ACS: acute coronary syndrome, MI: myocardial infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting.
